Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2014

01-10-2014 | Original paper

Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma

Authors: Shaowei Wu, Helen Kuo, Wen-Qing Li, Alvaro Laga Canales, Jiali Han, Abrar A. Qureshi

Published in: Cancer Causes & Control | Issue 10/2014

Login to get access

Abstract

Purpose

Previous studies suggest that solar UV exposure in early life is predictive of cutaneous melanoma risk in adulthood, whereas the relation of BRAF mutation with sun exposure and disease prognosis has been less certain. We investigated the associations between BRAFV600E and NRASQ61R mutations and known risk factors, clinicopathologic characteristics and clinical outcomes of melanoma in a case series of primary invasive cutaneous melanoma from the Nurses’ Health Study (NHS).

Methods

Somatic BRAFV600E and NRASQ61R mutations of 127 primary invasive melanomas from the NHS cohort were determined by pyrosequencing using formalin-fixed, paraffin-embedded block tissues. Logistic regression analyses were performed to detect the associations of mutations with melanoma risk factors, and Kaplan–Meier method was used to examine associations between mutations and survival.

Results

The odds ratios for harboring BRAFV600E mutations were 5.54 (95 % CI 1.19–25.8, p trend = 0.02) for women residing in states with UV index ≥ 7 versus those residing in states with UV index ≤5 at 30 years of age. Patients with BRAFV600E mutations tended to have shorter melanoma-specific survival when compared to patients with wild type at both loci (median survival time 110 vs. 159 months) (p = 0.03). No association was found between NRASQ61R mutation and melanoma risk factors or melanoma-specific survival.

Conclusions

BRAFV600E mutations in primary cutaneous melanomas were associated with residence in locations with medium and high UV indices in mid-life. BRAFV600E mutation may be associated with an unfavorable prognosis among melanoma patients.
Appendix
Available only for authorised users
Literature
1.
Geller AC, Miller DR, Annas GD et al (2002) Melanoma incidence and mortality among US whites, 1969–1999. JAMA 288:1719–1720PubMedCrossRef
2.
Jemal A, Devesa SS, Hartge P et al (2001) Recent trends in cutaneous melanoma incidence among Whites in the United States. J Natl Cancer Inst 93:678–683PubMedCrossRef
3.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
4.
Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44PubMedCrossRef
5.
Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059PubMedCrossRef
6.
Hacker E, Hayward NK, Dumenil T et al (2010) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130(1):241–248PubMedCrossRef
7.
Qureshi AA, Zhang M, Han J (2011) Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 21(3):197–203PubMedCentralPubMedCrossRef
8.
Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41:45–60PubMedCrossRef
9.
Whiteman DC, Watt P, Purdie DM et al (2003) Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95:806–812PubMedCrossRef
10.
Whiteman DC, Stickley M, Watt P et al (2006) Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172–3177PubMedCrossRef
11.
Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRef
12.
Landi MT, Bauer J, Pfeiffer RM et al (2006) MC1R germline variants confer risk for BRAF -mutant melanoma. Science 313:521–522PubMedCrossRef
13.
Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878–1890PubMedCrossRef
14.
Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef
15.
Goydos JS, MannB Kim HJ et al (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362–370PubMedCrossRef
16.
van Elsas A, Zerp SF, van der Flier S et al (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883–893PubMedCentralPubMed
17.
Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229–235PubMedCentralPubMedCrossRef
18.
Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14:105–114PubMedCrossRef
19.
Meier F, Schittek B, Busch S et al (2005) The RAS/RAF/MEK/ERK and PI3 K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986–3001PubMedCrossRef
20.
Kudchadkar RR, Smalley KS, Glass LF et al (2013) Targeted therapy in melanoma. Clin Dermatol 31(2):200–208PubMedCrossRef
21.
Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478PubMedCrossRef
22.
Autier P, Doré JF (1998) Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 77(4):533–537PubMedCrossRef
23.
Qureshi AA, Laden F, Colditz GA et al (2008) Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med 168(5):501–507PubMedCrossRef
24.
Whiteman DC, Whiteman CA, Green AC (2001) Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12:69–82PubMedCrossRef
25.
Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164(4):776–784PubMedCrossRef
26.
Thomas NE, Edmiston SN, Alexander A et al (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991–997PubMedCrossRef
27.
Venesio T, Chiorino G, Balsamo A et al (2008) In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 21:716–726PubMedCrossRef
28.
Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905PubMedCrossRef
29.
Thomas NE, Berwick M, Cordeiro-Stone M (2006) Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126:1693–1696PubMedCrossRef
30.
Willmore-Payne C, Holden JA, Tripp S, Layfield LJ (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36(5):486–493PubMedCrossRef
31.
Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16(4):267–273PubMedCrossRef
32.
Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246PubMedCrossRef
33.
Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666–672PubMedCrossRef
34.
Akslen LA, Angelini S, Straume O et al (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312–317PubMed
35.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516PubMedCentralPubMedCrossRef
36.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114PubMedCrossRef
37.
Sivertsson A, Platz A, Hansson J, Lundeberg J (2002) Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 48:2164–2170PubMed
Metadata
Title
Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma
Authors
Shaowei Wu
Helen Kuo
Wen-Qing Li
Alvaro Laga Canales
Jiali Han
Abrar A. Qureshi
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 10/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0443-x

Other articles of this Issue 10/2014

Cancer Causes & Control 10/2014 Go to the issue

Original paper

ABO blood group and esophageal carcinoma risk: from a case–control study in Chinese population to meta-analysis

Commentary

Breast screening: an obsessive compulsive disorder

Original paper

Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis

Original paper

Parental occupational paint exposure and risk of childhood leukemia in the offspring: findings from the Childhood Leukemia International Consortium

Original paper

Mortality from lymphohematopoietic neoplasms and other causes in a cohort of laminated plastic workers exposed to formaldehyde

Original paper

Maternal consumption of coffee and tea during pregnancy and risk of childhood brain tumors: results from an Australian case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits